WO2023062575 - CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS
National phase entry is expected:
Publication Number
WO/2023/062575
Publication Date
20.04.2023
International Application No.
PCT/IB2022/059817
International Filing Date
13.10.2022
Title **
[English]
CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS
[French]
COMPOSÉS DE SULFONE DE VINYLE CYCLIQUE UTILISÉS EN TANT QU'INHIBITEURS DE WRN
Applicants **
IDEAYA BIOSCIENCES, INC.
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
Inventors
ADAMS, Ashley
BURGESS, Joelle Lorraine
BURY, Michael J.
DEMARTINO, Michael P.
DOWDELL, Sarah E.
GLOGOWSKI, Michal Pawel
GODFREY, Nicole
GRAYBILL, Todd L.
MANNS, Sharada
MURPHY, Dennis
NEVINS, Neysa
RIDGERS, Lance Howard
SHEARER, Barry George
SHENJE, Raynold
TALLANT, Matthew
YING, Maben
JESO, Valer
PHELAN, James P.
JONES, Brian T.
TAYGERLY, Joshua P.G.
Priority Data
63/255,618
14.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3984 | |
| EPO | Filing, Examination, Granting | 21336 | |
| Japan | Filing, Examination, Granting | 2607 | |
| South Korea | Filing, Examination, Granting | 2826 | |
| USA | Filing, Examination, Granting | 10090 |
Total:
40,843
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are certain succinamido derivatives of Formula (I): (I) that inhibit Wemer Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are thereofore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.[French]
L'invention concerne certains dérivés succinamido de Formule (I) : (I) qui inhibent l'enzyme hélicase ATP-dépendante du syndrome de Wemer (WRN), en particulier inhibent l'activité du domaine hélicase WRN et sont utiles dans le traitement de cancers pouvant être traités par inhibition de WRN, y compris des cancers caractérisés par une instabilité des microsatellites (MSI) et/ou un système de réparation des mésappariements ADN défectueux (dMMR). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés d'utilisation de tels composés, et des procédés de fabrication de ceux-ci.